These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19860897)

  • 1. Role of L2 cysteines in papillomavirus infection and neutralization.
    Gambhira R; Jagu S; Karanam B; Day PM; Roden R
    Virol J; 2009 Oct; 6():176. PubMed ID: 19860897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes.
    Campos SK; Ozbun MA
    PLoS One; 2009; 4(2):e4463. PubMed ID: 19214230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell surface-binding motifs of L2 that facilitate papillomavirus infection.
    Yang R; Day PM; Yutzy WH; Lin KY; Hung CF; Roden RB
    J Virol; 2003 Mar; 77(6):3531-41. PubMed ID: 12610128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
    Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
    Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A protective and broadly cross-neutralizing epitope of human papillomavirus L2.
    Gambhira R; Karanam B; Jagu S; Roberts JN; Buck CB; Bossis I; Alphs H; Culp T; Christensen ND; Roden RB
    J Virol; 2007 Dec; 81(24):13927-31. PubMed ID: 17928339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies.
    Rubio I; Seitz H; Canali E; Sehr P; Bolchi A; Tommasino M; Ottonello S; Müller M
    Virology; 2011 Jan; 409(2):348-59. PubMed ID: 21074234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
    Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
    PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overlapping and independent structural roles for human papillomavirus type 16 L2 conserved cysteines.
    Conway MJ; Alam S; Christensen ND; Meyers C
    Virology; 2009 Oct; 393(2):295-303. PubMed ID: 19733888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.
    Alphs HH; Gambhira R; Karanam B; Roberts JN; Jagu S; Schiller JT; Zeng W; Jackson DC; Roden RB
    Proc Natl Acad Sci U S A; 2008 Apr; 105(15):5850-5. PubMed ID: 18413606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of multimeric human papillomavirus L2 vaccines.
    Jagu S; Kwak K; Karanam B; Huh WK; Damotharan V; Chivukula SV; Roden RB
    PLoS One; 2013; 8(1):e55538. PubMed ID: 23383218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.
    Kawana Y; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    J Virol; 2001 Mar; 75(5):2331-6. PubMed ID: 11160736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection.
    Bossis I; Roden RB; Gambhira R; Yang R; Tagaya M; Howley PM; Meneses PI
    J Virol; 2005 Jun; 79(11):6723-31. PubMed ID: 15890910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.
    Wang JW; Jagu S; Wu WH; Viscidi RP; Macgregor-Das A; Fogel JM; Kwak K; Daayana S; Kitchener H; Stern PL; Gravitt PE; Trimble CL; Roden RB
    Clin Vaccine Immunol; 2015 Jul; 22(7):806-16. PubMed ID: 25972404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
    Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
    Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.
    Day PM; Pang YY; Kines RC; Thompson CD; Lowy DR; Schiller JT
    Clin Vaccine Immunol; 2012 Jul; 19(7):1075-82. PubMed ID: 22593236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2.
    Nakao S; Mori S; Kondo K; Matsumoto K; Yoshikawa H; Kanda T
    Virology; 2012 Dec; 434(1):110-7. PubMed ID: 23051711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
    Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
    J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Furin Cleavage of L2 during Papillomavirus Infection: Minimal Dependence on Cyclophilins.
    Bronnimann MP; Calton CM; Chiquette SF; Li S; Lu M; Chapman JA; Bratton KN; Schlegel AM; Campos SK
    J Virol; 2016 Jul; 90(14):6224-6234. PubMed ID: 27122588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.